SciSparc has commenced the clinical trial of its new therapy, SCI-210, to treat ASD symptoms in children.

ASD differs widely among those it affects, presenting challenges in social interaction and communication.

The double-blind, randomised and placebo-controlled study has been initiated at the Soroka Medical Center in Israel.

SCI-210 is a combination of cannabidiol (CBD) and SciSparc’s Palmitoylethanolamide, designed to alleviate ASD symptoms.

SciSparc will enrol 60 subjects aged between five and 18 years over 20 weeks for scientifically measuring how the therapy compares to standard CBD treatment in managing symptoms of ASD.

SciSparc CEO Oz Adler said: “Our pioneering treatment aims to reduce and alleviate the symptoms of autism along with reducing the side effects that are common when taking cannabis-based treatments, such as CBD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“Partnering with the Soroka Medical Center and the National Autism Research Center, we are exploring new territory in ASD treatment.

“We are driven by science and the goal of improving life quality for children with ASD and their families.”

During this month, SciSparc started a Phase IIb clinical study of SCI-110 to treat patients with Tourette Syndrome.

The study is being conducted under the regulation of the US Food and Drug Administration (FDA), the Israeli Ministry of Health, and the Federal Institute for Drugs and Medical Devices in Germany.

The company commenced the trial at the Tel Aviv Sourasky Medical Center and is anticipated to continue with its medical sites in Germany and the US.